Abstract
Acute pancreatitis (AP) is a rare but serious complication of intragastric balloon (IGB) therapy. Despite the popularity of IGBs for weight loss, the incidence and risk factors of AP post-IGB insertion are not well understood. This study aimed to identify potential predictors and risk factors of AP in IGB patients. A retrospective time-to-event study was conducted over 7years, encompassing patients who received IGBs between January 2017 and 2024. Cox regression analyses were performed to identify risk factors. The incidence of AP was evaluated as a secondary outcome. Patients were categorized into the AP and non-AP groups at a 1:3 ratio. The Revised Atlanta Classification was used to diagnose AP. Among 450 patients with IGB, 25 developed AP, yielding an incidence of 5.56%. The Orbera balloon was associated with a lower AP risk (HR 0.29, 95% CI: 0.09-0.96; P = 0.042). The median time to AP onset was 40days. Higher preprocedural BMI and age > 30years showed a trend toward reduced AP risk, though not statistically significant. AP following IGB insertion is uncommon but may be underreported, with substantial variability in onset time. The Orbera balloon demonstrated a protective effect, highlighting the role of balloon type in AP risk. These findings underscore the importance of balloon selection and the need for further prospective studies to confirm these results and optimize AP risk management in IGB patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call